OTCMKTS:PHMMF Pharma Mar (PHMMF) Stock Price, News & Analysis $75.00 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest About Pharma Mar Stock (OTCMKTS:PHMMF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharma Mar alerts:Sign Up Key Stats Today's Range$75.00▼$75.0050-Day Range$34.26▼$75.0052-Week Range$26.85▼$75.00VolumeN/AAverage Volume34 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewPharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.Read More… Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Pharma Mar Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks3rd Percentile Overall ScorePHMMF MarketRank™: Pharma Mar scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pharma Mar.Read more about Pharma Mar's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPharma Mar has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the outstanding shares of Pharma Mar have been sold short.Short Interest Ratio / Days to CoverPharma Mar has a short interest ratio ("days to cover") of 123, which indicates bearish sentiment.Change versus previous monthShort interest in Pharma Mar has recently decreased by 30.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharma Mar does not currently pay a dividend.Dividend GrowthPharma Mar does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the outstanding shares of Pharma Mar have been sold short.Short Interest Ratio / Days to CoverPharma Mar has a short interest ratio ("days to cover") of 123, which indicates bearish sentiment.Change versus previous monthShort interest in Pharma Mar has recently decreased by 30.90%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentPharma Mar has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pharma Mar this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharma Mar insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.88% of the stock of Pharma Mar is held by insiders.Read more about Pharma Mar's insider trading history. Receive PHMMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma Mar and its competitors with MarketBeat's FREE daily newsletter. Email Address PHMMF Stock News HeadlinesNew miRNA inhibitor could extinguish the 'inflammatory fire' that stroke causes in the brainOctober 29, 2024 | msn.comPHMMF Pharma Mar, S.A.October 10, 2024 | seekingalpha.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…November 2, 2024 | Porter & Company (Ad)Chemists develop modular approach for creating important class of pharmaceutical compoundsJuly 19, 2024 | msn.comRevolutionizing Pharmaceutical Manufacturing: The Visionary Work of Tejesh MarsaleMay 18, 2024 | markets.businessinsider.comTransforming Pharmaceutical Manufacturing: The Visionary Work of Tejesh MarsaleMay 16, 2024 | msn.comPharming Group’s Strong Performance and Growth Prospects Justify Buy RatingMarch 18, 2024 | markets.businessinsider.comMar-a-lagoMarch 16, 2024 | newsweek.comSee More Headlines PHMMF Stock Analysis - Frequently Asked Questions How have PHMMF shares performed this year? Pharma Mar's stock was trading at $46.26 at the start of the year. Since then, PHMMF shares have increased by 62.1% and is now trading at $75.00. View the best growth stocks for 2024 here. How do I buy shares of Pharma Mar? Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today11/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:PHMMF Previous SymbolNASDAQ:PHMMF CUSIPN/A CIKN/A Webwww.pharmamar.com Phone(491) 846-6000Fax34-91-846-6001Employees509Year Founded1986Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.14 Current Ratio2.55 Quick Ratio2.01 Sales & Book Value Annual Sales$171.15 million Price / SalesN/A Cash Flow$0.41 per share Price / Cash Flow181.08 Book Value$11.62 per share Price / Book6.45Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.46 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:PHMMF) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma Mar, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharma Mar With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.